Targeting PCSK9 to reduce residual risk in ACS
- PMID: 30478399
- DOI: 10.1038/s41569-018-0125-6
Targeting PCSK9 to reduce residual risk in ACS
Comment on
-
Sorafenib for Advanced and Refractory Desmoid Tumors.N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052. N Engl J Med. 2018. PMID: 30575484 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
